References
- Wang N, Wei Y, Zhou G, Zhang Y, Song J. Acute coronary syndrome in an
8-year-old child with familial hypercholesterolemia: a case report. J
Med Case Reports [Internet]. 2022 [cited 2023 Jun 10];16.
Available from: https://www.ncbi.nlm.nih.gov/pmc /articles/PMC9316422.
- Bujo H, Takahashi K,
Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, et al. Clinical
features of familial hypercholesterolemia in Japan in a database from
1996− 1998 by the Research Committee of the Ministry of Health, Labour
and Welfare of Japan. J Atheroscler Thromb. 2004;11(3):146–51.
- Motozato K, Sueta D,
Sakamoto K, Nagamatsu S, Yamashita T, Sato R, et al. A case of
repetitive acute coronary syndrome in a patient with familial
hypercholesterolemia. J Cardiol Cases. 2019 Dec;20(6):200.
- Group SBR. Risk of
fatal coronary heart disease in familial hypercholesterolaemia. BMJ.
1991;893–6.
- Austin MA, Hutter
CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous
familial hypercholesterolemia: a HuGE prevalence review. Am J
Epidemiol. 2004;160(5):407–20.
- Kumar P, Prasad SR,
Anand A, Kumar R, Ghosh S. Prevalence of familial hypercholesterolemia
in patients with confirmed premature coronary artery disease in
Ranchi, Jharkhand. Egypt Heart J [Internet]. 2022 Dec [cited
2023 Jun 16];74. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759604/
- Feng S, Zhao X, Wang
Y, Wang Y, Chen G, Zhang S. Autosomal Recessive Hypercholesterolemia
Caused by a Novel LDLRAP1 Variant and Membranous Nephropathy in a
Chinese Girl: A Case Report. Front Cardiovasc Med. 2022;9:811317.
- Nemati MH. Coronary
revascularization in a child with homozygous familial
hypercholesterolemia. Interact Cardiovasc Thorac Surg. 2010
Jan;10(1):131–2.
- Harada-Shiba M, Arai
H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the
management of familial hypercholesterolemia. J Atheroscler Thromb.
2012;19(12):1043–60.
- Nordestgaard BG,
Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al.
Familial hypercholesterolaemia is underdiagnosed and undertreated in
the general population: guidance for clinicians to prevent coronary
heart disease: consensus statement of the European Atherosclerosis
Society. Eur Heart J. 2013;34(45):3478–90.
- Williams RR, Hunt
SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing
heterozygous familial hypercholesterolemia using new practical
criteria validated by molecular genetics. Am J Cardiol.
1993;72(2):171–6.
- Al-Rasadi K,
Al-Waili K, Al-Sabti HA, Al-Hinai A, Al-Hashmi K, Al-Zakwani I, et al.
Criteria for Diagnosis of Familial Hypercholesterolemia: A
Comprehensive Analysis of the Different Guidelines, Appraising their
Suitability in the Omani Arab Population. Oman Med J. 2014
Mar;29(2):85.
- Ockene IS, Chiriboga
DE, Stanek III EJ, Harmatz MG, Nicolosi R, Saperia G, et al. Seasonal
variation in serum cholesterol levels: treatment implications and
possible mechanisms. Arch Intern Med. 2004;164(8):863–70.
- Jansen ACM, van
Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The
contribution of classical risk factors to cardiovascular disease in
familial hypercholesterolaemia: data in 2400 patients. J Intern Med.
2004 Dec;256(6):482–90.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel
RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz
JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines. 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014
Jul 1;63(25 Pt B):2889-934.
- Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E,
Kastelein JJP, Hutten BA. 20-Year Follow-up of Statins in Children
with Familial Hypercholesterolemia. N Engl J Med. 2019 Oct
17;381(16):1547-1556.
- Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins
in Familial Hypercholesterolemia: Consequences for Coronary Artery
Disease and All-Cause Mortality. J Am Coll Cardiol. 2016 Jul
19;68(3):252-260.
- Pradhan A, Bhandari M, Sethi R. Ezetimibe and Improving Cardiovascular
Outcomes: Current Evidence and Perspectives. Cardiol Res Pract. 2020
Jun 28;2020:9815016.
- Pradhan A, Bhandari M, Vishwakarma P, Singh A, Perrone MA, Sethi R.
Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density
Lipoprotein (LDL) Cholesterol. J Cardiovasc Dev Dis. 2023 Apr
27;10(5):195.
- Raal FJ, Stein EA,
Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with
evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia
(RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
The Lancet. 2015;385(9965):331–40.
- Kastelein JJ,
Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY
FH I and FH II: 78 week results with alirocumab treatment in 735
patients with heterozygous familial hypercholesterolaemia. Eur Heart
J. 2015;36(43):2996–3003.
- Rosenson RS. Existing and emerging therapies for the treatment of
familial hypercholesterolemia. J Lipid Res. 2021;62:100060.
- Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA,
Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L,
Kastelein JJP; ORION Phase III Investigators. Pooled Patient-Level
Analysis of Inclisiran Trials in Patients With Familial
Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar
9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. PMID: 33663735.
- Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P,
Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM,
Yancopoulos GD, Zhang Y, Gaudet D; ELIPSE HoFH Investigators.
Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med.
2020 Aug 20;383(8):711-720.
- Vafai SB, Gladding PA, Scott R et al. Safety and Pharmacodynamic
Effects of VERVE-101, an Investigational DNA Base Editing Medicine
Designed to Durably Inactivate the PCSK9 Gene and Lower LDL
Cholesterol - Interim Results of the Phase 1b heart-1 Trial (LBS
23230).Late-Breaking Science Abstracts and Featured Science Abstracts
From the American Heart Association’s Scientific Sessions 2023 and
Late-Breaking Abstracts in Resuscitation Science From the
Resuscitation Science Symposium 2023. Circulation.
2023;148:e290–e291. DOI: 10.1161/CIR.0000000000001200.
- Ungar L, Sanders D,
Becerra B, Barseghian A. Percutaneous Coronary Intervention in
Familial Hypercholesterolemia Is Understudied. Front Cardiovasc Med.
2018;5:116.
- Datta BN, McDowell
IF, Rees A. Integrating provision of specialist lipid services with
cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol.
2010;21(4):366–71.